MSLE MSLE
Company Profile ↓Company Overview
MSLE (MSLE) is a publicly traded company listed on with a market capitalization of $154.74M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +102.47% |
| 6 Months: | -13.33% |
| 3 Months: | +25.12% |
| 1 Month: | +21.92% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.63 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 6.48M | 6.37M | 5.97M | 7.65M | 10.04M |
| Operating Income | - | -6.48M | -6.37M | -5.97M | -7.65M | -10.04M |
| EBITDA | - | -6.48M | -6.37M | -5.96M | -7.65M | -10.04M |
| Interest Expense | 0 | - | - | - | - | - |
| Pretax Income | - | -6.08M | -5.58M | -5.80M | -7.25M | -9.73M |
| Tax Provision | - | 63.00K | 32.00K | 19.00K | 58.00K | 33.00K |
| Net Income | - | -6.14M | -5.61M | -5.82M | -7.30M | -9.77M |
| Diluted EPS | - | -0.44 | -0.36 | -0.36 | - | -0.53 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | 94.05K | - | - | - | - |
| Gross Profit | -94.05K | - | - | - | - |
| Operating Expenses | - | 6.21M | 11.66M | 20.40M | 26.46M |
| Operating Income | - | -6.21M | -11.66M | -20.40M | -26.46M |
| EBITDA | - | -8.09M | -11.84M | -20.38M | -26.45M |
| Interest Expense | 772.80K | 0 | 133.42K | 0 | - |
| Pretax Income | - | -8.34M | -11.98M | -20.63M | -24.70M |
| Tax Provision | - | 3.68K | 0 | 0 | 172.00K |
| Net Income | - | -8.34M | -11.98M | -20.63M | -24.87M |
| Diluted EPS | - | -2.83 | -1.63 | -2.16 | -1.70 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 4.57M | 33.49M | 50.75M | 31.89M |
| Current Assets | - | 1.65M | 30.48M | 50.74M | 31.88M |
| Cash & Equivalents | - | 1.42M | 16.68M | 40.07M | 9.80M |
| Inventory | - | - | - | - | - |
| Receivables | 1.40K | 0 | - | - | - |
| Total Liabilities | - | 2.09M | 2.73M | 3.58M | 4.11M |
| Current Liabilities | - | 2.09M | 2.73M | 3.58M | 4.11M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 2.48M | 30.76M | 47.16M | 27.78M |
| Shares Outstanding | - | 3.48M | 9.40M | 13.82M | 15.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.26M | -8.73M | -18.25M | -23.60M |
| Investing Cash Flow | - | -2.21K | -13.22M | 4.66M | -9.42M |
| Financing Cash Flow | - | 2.04M | 38.01M | 37.57M | 2.24M |
| Capital Expenditure | - | -2.21K | -13.57K | -4.00K | -6.00K |
| Free Cash Flow | - | -4.26M | -8.75M | -18.26M | -23.60M |
| Net Change in Cash | - | -2.12M | 16.06M | 23.98M | -30.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -336.1% | -38.9% | -43.7% | -89.5% |
| ROCE % | - | -250.2% | -37.9% | -43.2% | -95.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MSLE
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of ad…
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Recently listed, Satellos Bioscience Inc. (NASDAQ:MSLE) on Wednesday reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy (DMD) The data showed that SAT-3247-treated DMD patients exper…
Satellos Says Interim Phase 2 Data Shows SAT-3247 Improves Muscle Measures in Adult DMD Patients
Satellos Bioscience (MSLE) said Wednesday six-month interim data from a phase 2 trial showed that it
Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition All four participants showed an increase…
Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy (“Duchenne” or “DMD”)Fast Track is designed to expedite the development/review of new drugs to treat serious or li…
Satellos to Present Clinical Program Updates at ICNMD 2026
TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today anno…
MSLE — Frequently Asked Questions
What is the current share price of MSLE?
As of 2026-08-05 17:25 PDT, MSLE trades at $10.01 on NASDAQ/NYSE. Its 52-week range is $4.85 to $13.01.
What is the market capitalisation of MSLE?
MSLE has a market capitalisation of $154.74M on NASDAQ/NYSE.
What is the P/E ratio of MSLE?
MSLE trades at a trailing price-to-earnings (P/E) ratio of -5.89. Its price-to-book (P/B) ratio is 5.57.
What is the return on equity (ROE) of MSLE?
MSLE has a return on equity (ROE) of -89.52%. Its return on capital employed (ROCE) is -95.23%.
Is MSLE a good stock to buy?
This page provides a data-driven analysis of MSLE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.